lilly cease and desist tirzepatide eli letter Novo Nordisk sues over alleged false advertising for weight loss drugs Eli Lilly Issues Cease-And-Desist Letters

The quick answer: Semaglutide is a GLP-1 receptor agonist an injectable (and now oral) drug FDA-approved for long-term, chronic weight management , producing the larger weight loss but at meaningfully higher cost

Research indicates that this combination yields benefits such as improved deep sleep, reduced triglycerides, visceral adipose tissue, and carotid intima media thickness, enhanced cognition, and overall improved metabolic function

NEJM 2025

Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system

Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial